Rofecoxib

Drug Profile

Rofecoxib

Alternative Names: Ceoxx; MK 966; Vioxx; Vioxx Acute

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Merck & Co
  • Developer Banyu; CollaGenex Pharmaceuticals; Merck & Co; Merck Frosst
  • Class Antirheumatics; Lactones; Non-opioid analgesics; Sulfones
  • Mechanism of Action Cyclo-oxygenase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Market Withdrawal Dental pain; Dysmenorrhoea; Musculoskeletal disorders; Osteoarthritis; Pain; Rheumatoid arthritis
  • Discontinued Alzheimer's disease; Colorectal cancer; Familial adenomatous polyposis; Juvenile rheumatoid arthritis; Migraine; Periarthritis; Preterm labour; Sporadic adenomas

Most Recent Events

  • 21 Feb 2005 An advisory committee of the FDA has recommended that the risk-benefit profile for rofecoxib supports marketing in the USA
  • 11 Oct 2004 A clinical study has been added to the adverse events section
  • 01 Oct 2004 Discontinued - Clinical-Phase-Unknown for Juvenile rheumatoid arthritis in Europe (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top